Next-Generation Sequencing Reveals a Very Low Prevalence of Deleterious Mutations of Homologous Recombination Repair Genes and Homologous Recombination Deficiency in Ovarian Clear Cell Carcinoma

被引:4
|
作者
Liu, Hangqi [1 ]
Zhang, Zhiwen [1 ]
Chen, Longyun [1 ]
Pang, Junyi [1 ]
Wu, Huanwen [1 ]
Liang, Zhiyong [1 ]
机构
[1] Chinese Acad Med Sci & Peking Union Med Coll, Peking Union Med Coll Hosp, Mol Pathol Res Ctr, Dept Pathol,State Key Lab Complex Severe & Rare D, Beijing, Peoples R China
来源
FRONTIERS IN ONCOLOGY | 2022年 / 11卷
基金
中国国家自然科学基金;
关键词
ovarian clear cell carcinoma; homologous recombination repair gene; homologous recombination deficiency; molecular classification; next-generation sequencing; EXPRESSION; VARIANTS;
D O I
10.3389/fonc.2021.798173
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Ovarian clear cell carcinoma (OCCC) is aggressive and drug-resistant. The prevalence of homologous recombination repair (HRR) gene mutations and homologous recombination deficiency (HRD) remains largely unknown. It is also not clear whether the commonly used molecular-based classification for endometrial carcinoma (EC) is potentially applicable in OCCC. In this study, surgically resected samples were collected from 44 patients with OCCC. Genomic alterations were determined using next-generation sequencing. HRD was estimated by genomic instability. Of 44 patients with OCCC, two (4.5%) harbored likely pathogenic mutations in HRR genes. Notably, no pathogenic or likely pathogenic mutations were found in BRCA1/2. A total of 24 variants of uncertain significance (VUS) in HRR-related genes occurred in 18 (40.9%) patients. HRD was observed in only one case (2.3%). In addition, TP53 mutation and microsatellite instability-high (MSI-H) were identified in three patients (6.8%) and in one patient (2.3%), respectively. TP53 mutation was significantly associated with disease-free survival and overall survival. No POLE mutations were found. In conclusion, our results revealed a very low prevalence of HRR gene mutations and HRD in OCCC. Moreover, TP53 mutations and MSI-H are uncommon, while POLE mutations are extremely rare in OCCC. Our findings indicate that the evaluation of HRR gene mutations, HRD status, POLE mutations, and MSI-H may have limited clinical significance for OCCC treatment and prognostic stratification.
引用
收藏
页数:9
相关论文
共 50 条
  • [31] Assessing homologous recombination deficiency (HRD) in ovarian cancer: Optimizing concordance of the regulatory-approved companion diagnostic and a next-generation sequencing (NGS) assay kit.
    Weichert, Wilko
    Qiu, Ping
    Lunceford, Jared
    Wehn, Amy
    Yarunin, Alexander
    Cristescu, Razvan
    Liu, Li
    Roessler, Kyria
    Timms, Kirsten
    Marton, Matthew John
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E17571 - E17571
  • [32] Comparing mutation frequencies for homologous recombination genes in uterine serous and high-grade serous ovarian carcinomas: A case for homologous recombination deficiency testing in uterine serous carcinoma
    Wallbillich, J. J.
    Morris, R. T.
    Ali-Fehmi, R.
    GYNECOLOGIC ONCOLOGY, 2020, 159 : 45 - 46
  • [33] Comparing mutation frequencies for homologous recombination genes in uterine serous and high-grade serous ovarian carcinomas: A case for homologous recombination deficiency testing in uterine serous carcinoma
    Wallbillich, John J.
    Morris, Robert T.
    Ali-Fehmi, Rouba
    GYNECOLOGIC ONCOLOGY, 2020, 159 (02) : 381 - 386
  • [34] Rates of somatic variants in homologous recombination DNA repair deficiency genes in older patients with high-grade serous ovarian carcinoma
    Pitiyarachchi, Omali
    Lee, Yeh Chen
    Ramus, Susan J.
    deFazio, Anna
    Friedlander, Michael
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2022, 18 : 30 - 30
  • [35] Somatic and germline aberrations in homologous recombination repair genes among Chinese high-risk breast cancer patients by multi-gene next-generation sequencing
    Xie, Ling
    Chen, Jie
    Zheng, Yanying
    Sun, Yi
    Zhang, Xiang
    Chu, Lele
    Zhang, Yifen
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2024, : 660 - 670
  • [36] Diagnosis of Ovarian Carcinoma Homologous Recombination DNA Repair Deficiency From Targeted Gene Capture Oncology Assays
    Krumm, Niklas
    Khasnavis, Nithisha S.
    Radke, Marc
    Banda, Kalyan
    Davies, Helen R.
    Pennil, Christopher
    Mclean, Kathryn
    Paulson, Vera A.
    Konnick, Eric Q.
    Johnson, Winslow C.
    Huff, Grogan
    Nik-Zainal, Serena
    Swisher, Elizabeth M.
    Lockwood, Christina M.
    Salipante, Stephen J.
    JCO PRECISION ONCOLOGY, 2023, 7
  • [37] Concordance between single-nucleotide polymorphism–based genomic instability assays and a next-generation sequencing–based homologous recombination deficiency test
    Razvan Cristescu
    Xiao Qiao Liu
    Gladys Arreaza
    Cai Chen
    Andrew Albright
    Ping Qiu
    Matthew J. Marton
    BMC Cancer, 22
  • [38] Clinical evaluation of a low-coverage wholegenome sequencing test for homologous recombination deficiency detection in ovarian cancer
    Gottin, Celine
    Ruzicka, Jiri
    Duforet-Frebourg, Nicolas
    Bertrand, Denis
    Boidot, Romain
    Wissler, Marie-Pierre
    Philippe, Nicolas
    Blum, Michael
    EUROPEAN JOURNAL OF HUMAN GENETICS, 2024, 32 : 570 - 570
  • [39] Evaluation of homologous recombination repair (HRR) status in metastatic prostate cancer by next-generation sequencing and functional tissue-based immunofluorescence assays
    Morgado, Pablo Cresta
    Arce-Gallego, Sara
    Delgado-Serrano, Luisa
    Simonetti, Sara
    Gonzalez, Macarena
    Castaneda, David Humberto Marmolejo
    Morales-Barrera, Rafael
    Planas, Jacques
    Romero-Lozano, Paula
    Maldonado, Xavier
    Suarez, Cristina
    Figols, Mariona
    Cros, Sara
    Dienstmann, Rodrigo
    Nuciforo, Paolo
    Vivancos, Ana
    Llop-Guevara, Alba
    Carles, Joan
    Serra, Violeta
    Mateo, Joaquin
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [40] Migrating the SNP array-based homologous recombination deficiency measures to next generation sequencing data of breast cancer
    Sztupinszki, Zsofia
    Diossy, Miklos
    Krzystanek, Marcin
    Reiniger, Lilla
    Csabai, Istvan
    Favero, Francesco
    Birkbak, Nicolai J.
    Eklund, Aron C.
    Syed, Ali
    Szallasi, Zoltan
    NPJ BREAST CANCER, 2018, 4